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Abstract
Endometriosis is defined as the presence of endometrial tissue outside the uterus. It affects 10–15% of women during
reproductive age and has a big personal and social impact due to chronic pelvic pain, subfertility, loss of work-hours and
medical costs. Such conditions are exacerbated by the fact that the correct diagnosis is made as late as 8–11 years after
symptom presentation. This is due to the lack of a reliable non-invasive diagnostic test and the fact that the reference
diagnostic standard is laparoscopy (invasive, expensive and not without risks). High-molecular weight gadofosveset-
trisodium is used as contrast agent in Magnetic Resonance Imaging (MRI). Since it extravasates from hyperpermeable
vessels more easily than from mature blood vessels, this contrast agent detects angiogenesis efficiently. Endometriosis has
high angiogenic activity. Therefore, we have tested the possibility to detect endometriosis non-invasively using Dynamic
Contrast-Enhanced MRI (DCE-MRI) and gadofosveset-trisodium as a contrast agent in a mouse model. Endometriotic lesions
were surgically induced in nine mice by autologous transplantation. Three weeks after lesion induction, mice were scanned
by DCE-MRI. Dynamic image analysis showed that the rates of uptake (inwash), persistence and outwash of the contrast
agent were different between endometriosis and control tissues (large blood vessels and back muscle). Due to the extensive
angiogenesis in induced lesions, the contrast agent persisted longer in endometriotic than control tissues, thus enhancing
the MRI signal intensity. DCE-MRI was repeated five weeks after lesion induction, and contrast enhancement was similar to
that observed three weeks after endometriosis induction. The endothelial-cell marker CD31 and the pericyte marker a-
smooth-muscle-actin (mature vessels) were detected with immunohistochemistry and confirmed that endometriotic lesions
had significantly higher prevalence of new vessels (CD31 only positive) than the uterus and control tissues. The diagnostic
value of gadofosveset-trisodium to detect endometriosis should be tested in human settings.
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Introduction
Endometriosis is defined as the presence of endometrial tissue
outside the uterus. It affects 10–15% of women during
reproductive age and has a big personal and social impact due
to chronic pelvic pain, morbidity, subfertility and high health-care
costs [1–4]. Endometriosis presents as superficial peritoneal
implants, as lesions located on the ovaries (endometriomas) or as
deeply invasive nodules, which can infiltrate different organs
(rectum, bladder, uterus) compromising their functionality [1,3].
Despite the fact that important progress has been made in the
genetic, the molecular and the hormonal mechanisms underlying
its pathogenesis [5–10], one of the major clinical issues in the
management of this disorder is the diagnosis. Initially based on
symptoms, medical history and physical examination, the correct
diagnosis is delayed for up to 8–11 years after the first complaints
have been reported. This is due to the fact that symptoms are
similar to other urogenital disturbances and that a non-invasive
diagnostic test is lacking [3,11,12]. Ultrasound and magnetic
resonance imaging (MRI) help diagnosing endometriomas and
deeply invasive lesions [13]. However, peritoneal implants,
occurring in most of the patients even in the presence of lesions
at other locations, are not detected by these methods [14,15]. In
the end, the reference diagnostic standard is laparoscopy, which is
invasive, expensive and not free of risks. Scientists and physicians
have therefore recognised that the development of a non-invasive
diagnostic tool is a priority in endometriosis research [16].
In the pathogenesis of endometriosis, novel blood vessels are
formed [1,12,17–19]. Angiogenesis can be visualised by Dynamic
Contrast-Enhanced MRI (DCE-MRI) using gadolinium-based
contrast agents [20–24]. However, this technique has shown
already little accuracy and a sensitivity lower than 40% in
diagnosing peritoneal endometriosis [14,15,25].
Recent experience in oncology, has underscored that high-
molecular weight contrast agents detect novel blood vessels with
higher accuracy, contrast and sensitivity than low-molecular
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a gadolinium-based contrast, which forms a complex with albumin
in the blood, hence becomes a macromolecule [28]. This complex
extravasates easily for immature hyperpermeable blood vessels but
not (or much slower) from mature vasculature. As a result, the
signal from angiogenic spots is enhanced. Gadofosveset-trisodium
is well characterised for angiography and for colorectal cancer
diagnosis [20–24,26–28]. Its use in diagnosing endometriosis has
never been explored. Therefore, we devised an experimental study
in which the detection of surgically induced endometriotic lesions
in a small-animal model was evaluated by DCE-MRI using
gadofosveset-trisodium as a contrast agent. Our results show that
endometriosis-associated angiogenesis could be visualised by this
method in mice, which implies diagnostic potential in patients in
the near future.
Results
Endometriotic lesions induction
Lesions were surgically induced by autologous transplantation
[29] in nine female mice (two lesions per mouse). At time of
surgery, six mice were in the di-estrous phase of the estrous cycle
and three, in the pro-estrous phase (scheme in Figure 1). One
uterine horn from each mouse was removed and opened
longitudinally. Two fragments of about 2–3 mm
2 were sutured
to the abdominal wall of the same mouse at opposite abdomen
sites, either subcutaneously or intraperitoneally (Figure 2A).
Six mice were sacrificed three weeks after endometriosis
induction (just after MRI scans), whereas three mice were
maintained for five weeks after endometriosis induction and were
scanned for a second time. At sacrifice, macroscopic inspection
revealed the presence of both subcutaneous and intraperitoneal
lesions (Figure 2B). No significant size differences were measured
between subcutaneously and intraperitoneally induced endome-
triosis (Figure 2C). In each mouse, the size of the lesions in the two
locations was correlated (Figure 2D). No difference was observed
among lesions induced at distinct phases of the estrous cycle.
Histology revealed the presence of typical endometriosis, with
cystic or with organised endometrial tissue characteristics
(Figure 3). No difference in the histology was observed between
subcutaneous and intraperitoneal endometriosis.
Gadofosveset-trisodium enhancement characteristics
Three weeks after endometriosis induction, all mice were
subjected MRI (scheme in Figure 1). Five mice were in the di-
estrous phase, three in the pro-estrous and one in the meta-estrous
phase of the cycle. Anatomical T2 and T1 weighted images were
acquired prior and post gadofosveset-trisodium administration to
visualise the lesions. The induced endometriotic implants could be
clearly visualised (Figure 4A). The signal intensity in distinct areas
could be subsequently measured through the serial scanned
images. After the injection (‘INJ’ in Figure 4B), the contrast almost
immediately entered the circulation (inwash phase; ‘I’ in
Figure 4B). As expected, the large abdominal vessels (combination
of the aorta and vena cava) showed a more rapid enhancement
(steeper curve) than the tissues of back muscle and endometriotic
lesions, indicating the entrance of the contrast agent in the
circulatory system after the injection. The inwash phase was
followed by a phase during which the contrast agent steadily
circulated (‘C’ in Figure 4B) and finally was cleared during the
outwash phase (‘O’ in Figure 4B). In the large abdominal vessels
and the back muscle (used as a control of a non-angiogenic tissue)
a relatively fast outwash phase was observed, indicated by the
decrease of the signal intensity. In the subcutaneous as well as in
the intraperitoneal lesions, on the contrary, no signal decrease was
observed, indicating that the contrast had extravasated from
immature blood vessels into the interstitial space of the
surrounding endometriotic tissue, thus enhancing signal MRI
intensity.
To quantify the extent of extravasation of the contrast agent, the
ratios between washout and inwash (O/C) were computed for the
various tissues. The higher values of the O/C ratios in the lesions
compared with the control tissues (abdominal vessels and back
muscle) indicated that the contrast had extravasated and its
presence persisted in induced endometriosis. Contrarily, the low
O/C values (control tissues) indicated that the contrast had
remained in the blood vessels and washed-out, with little
extravasation (Figure 4C).
No difference was observed in the performance of the DCE-
MRI in mice at distinct estrous-phase periods. In three mice (one
during the di-estrous and two during the meta-estrous phase of the
cycle), DCE-MRI was repeated five weeks after lesion induction.
No significant differences were seen compared to the DCE-MRI
performed two weeks earlier (results not shown).
Endometriotic lesions surgically induced in mice are
highly angiogenic
To confirm the presence of angiogenesis in endometriosis,
immunohistochemistry was performed in six mice. Cluster of
differentiation 31 (CD31) is an endothelial cell marker expressed in
all blood vessels, whereas alpha-smooth-muscle-actin (aSMA) [30]
is a myofibroblast marker expressed in smooth muscle fibres
Figure 1. Scheme of the animal experiment. Endometriosis was surgically induced by autologous transplantation [29] in nine mice at DAY 0.
Three weeks (all nine mice) and five weeks later (three mice), animals were subjected to DCE-MRI.
doi:10.1371/journal.pone.0033241.g001
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vessels [31]. The number of new blood vessels (CD31 only
positive) and the number of mature (aSMA positive) blood vessels
was assessed in individual tissues (Figure 5).
In the uterus (eutopic endometrium), most CD31 positive blood
vessels also expressed aSMA. The myometrium can be easily
identified because it consists of aSMA positive fibro muscular cells
(Figure 5A). In the (striated and therefore aSMA negative)
muscular tissues of the abdominal wall adjacent to the induced
endometriosis (peri-endometriotic tissue) most vessels were both
CD31 and aSMA positive (Figure 5B). In contrast, in the
endometrial layer of both intraperitoneal and subcutaneous lesions
(Figure 5C and 5D, respectively), only CD31 positive blood vessels
were present, indicating angiogenesis. In this mouse-model, the
myometrium was transplanted together with the endometrium,
and consisted of aSMA positive cells. This myometrial layer could
be easily recognised between the endometrium and the tissues
surrounding the lesions (Figure 5B and 5D).
Quantification of the number of CD31 and aSMA positive
blood vessels in various tissues (vessel density) showed that in both
intraperitoneal and subcutaneous endometriosis, the number of
CD31 vessels largely exceeded the number of aSMA positive
Figure 2. Endometriosis was induced in mice. A. Autologous transplantation [29]: one uterine horn from one mouse is removed, opened
longitudinally, and two 2–3 mm
2 uterine fragments are sutured to the abdominal wall of the same mouse either subcutaneously (left) or
intraperitoneally (right). B. At sacrifice, macroscopic inspection revealed the presence of both subcutaneous (sc) and intraperitoneal (ip) lesions. C. No
significant size differences were seen between subcutaneous and intraperitoneal lesions. D. The size of the subcutaneous and intraperitoneal lesions
in each single mouse are plotted on the X and Y-axes, respectively, and showed a significant correlation (R
2=0.7930).
doi:10.1371/journal.pone.0033241.g002
Figure 3. Endometriosis was confirmed with histology. Haematoxylin and eosin staining was used to characterise histologically the lesions. ‘e’
indicates endometrial tissue; ‘m’=myometrium. Muscle fibres and fat tissue of the abdominal wall are indicated by: ‘mu’=muscle; ‘f’=fat;
‘abd’=abdominal cavity. The border between endometriosis and the abdominal wall is indicated by the yellow-dashed line.
doi:10.1371/journal.pone.0033241.g003
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and the muscular tissue of the abdominal wall adjacent to the
endometriosis lesions (peri-endometriotic tissue) or distant from
the lesions, equal numbers of CD31 and aSMA positive vessels
were observed (Figure 6A). This analysis was performed by
assessing independently the number of CD31 and the number of
aSMA positive blood vessels per tissue in each mouse and by
computing the average vessel density (from the six measured mice)
in each tissue (see also material and methods).
In an additionally analysis, to confirm that in each single mouse
the surgically induced endometriotic lesions had more CD31
positive vessels than the control tissues, the ratio between the
number of CD31 and aSMA positive vessels in each tissue per
mouse was determined. Figure 6B illustrates the average CD31/
aSMA ratio, which was computed out of the six mice.
Endometriotic lesions had about a five-fold increased number of
newly formed vessels than the eutopic endometrium. As expected,
the endometrium inside the uterus itself had higher angiogenesis
than the muscular tissue present in the abdominal wall, as
indicated by the increased quantity of newly formed vessels (higher
CD31/aSMA ratio) in the (eutopic) endometrium compared with
the muscular tissue (Figure 6B).
Discussion
Current findings
Gadofosveset-trisodium detects novel blood vessels with high
accuracy, contrast and sensitivity [26–28] therefore it has been
extensively used for angiography and in cancer-associated
angiogenesis [20–24,26–28].
Angiogenesis has been investigated in endometriosis using
mouse models consisting of transplanted murine as well as human
endometrial tissues. The formation of novel blood vessels
characterises these lesions, and blockade of angiogenesis impairs
their growth [1,12,17–19]. A recent investigation using a mouse
model has clearly shown that endothelial progenitor stem cells are
increased in mice with induced endometriosis compared with
controls, and that these cells are recruited to endometriosis and
form neo-vasculature [19].
In the present study, endometriotic lesions were surgically
induced in mice at two anatomical locations: intraperitoneally and
subcutaneously. Neither difference in size, nor in histological
features were observed between intraperitoneal and subcutaneous
lesions, indicating that the growth/maintenance of the induced
endometriosis was not influenced by the implantation location.
Additionally, using this model, we demonstrated that gadofos-
veset-trisodium enhanced MRI could detect the induced endo-
metriotic lesions because of the high angiogenic activity of the
transplanted endometrium. This was confirmed in the studied
animals by the higher prevalence of novel blood vasculature
present in endometriosis compared with the endometrium inside
the uterus (eutopic) and with non-angiogenic control tissues.
Translation to human pathology
Despite MRI has proven a good diagnostic power for deeply
invasive and ovarian endometriosis [13,32] and in the recent
Figure 4. Endometriosis visualised by gadofosveset-trisodium enhanced MRI. Three weeks after lesion induction, mice were subjected to
gadofosveset-trisodium enhanced MRI. A. Examples of T2 weighted anatomical images and T1 weighted prior and post contrast injection in two
mice. Lesions are indicated by black arrow-heads (subcutaneous) and white arrow-heads (intraperitoneal). B. DCE-MRI derived intensity time-curves in
the large abdominal blood vessels, back muscle, intraperitoneal and subcutaneous lesions. Injection of gadofosveset-trisodium is indicated (arrow-
INJ). The inwash (I), circulation (C) and the outwash phases (O) of the contrast agent are indicated. Charts represent the average signal intensity of
nine mice plus SD. C. The ratio O/C was assessed in the large abdominal vessels, back muscle and endometriosis. Statistic based on unpaired
Wilcoxon test: *=0.001; **,0.001; ns=non-significant.
doi:10.1371/journal.pone.0033241.g004
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efficiency for these forms of endometriosis [33–35], peritoneal
implants, especially if superficial, cannot be diagnosed readily by
MRI [14,15,25].
The presence of strong angiogenic activity has been confirmed
in human endometriosis [1], where over 80% of the blood vessels
are pericyte-free. This exceeds the prevalence of new vessels in the
eutopic endometrium [36]. Therefore, the enhancing properties of
gadofosveset-trisodium could be helpful to detect endometriosis-
associated angiogenesis in humans. Since the disease model used
in this study resembles the superficial implants seen in women
(uterine fragments are sutured to the peritoneal cavity or
subcutaneously and do not deeply infiltrate other organs), our
results suggest that gadofosveset-trisodium enhanced MRI has the
potential to diagnose early endometriosis, including peritoneal
implants in humans.
It may be envisaged that distinct kinds of peritoneal implants
will be diagnosed with different sensitivities. For instance, red
peritoneal lesions, typically with high angiogenic activity [1], may
be diagnosed easier than black lesions (characterised by some
extent of pericyte deposition on blood vessels) [1] and that the
non-angiogenic white lesions may not be easily diagnosed.
However, it should be also noted that in a clinical perspective,
the highly angiogenic implants (especially the red ones) are
responsible for the most important symptoms in patients. In
addition, the most significant contribution of such non-invasive
diagnostic tool will be the diagnosis of endometriosis in adolescent
and in case of disease recurrence after treatment. These conditions
are expected to be characterised by the presence of newly formed
and highly angiogenic implants.
Gadofosveset-trisodium is clinically approved in several coun-
tries including the US and the EU, has a high tolerability and
Figure 5. Endometriosis is characterised by angiogenesis. Different tissues were stained by immunohistochemistry for CD31 (endothelial cell
marker) and the pericyte marker aSMA (present in mature vessels only). Representative images are shown. A. In the uterus (eutopic endometrium),
most CD31 positive blood vessels are also aSMA positive, indicated by the black arrow-heads in the enlargements. ‘e’=endometrium; ‘m’=aSMA
positive myometrial cells; ‘v’=large-mature blood vessels present in the myometrial layer. B. Abdominal wall consisting in large part of striated
muscular tissue (mu), with some connective (c) and fat (f) tissues. A surgically induced endometriotic lesion is present on the left image, and visiblea s
aSMA positive myometrial tissue (at the bottom-left of the low-magnification image; blue arrow-head). C & D. Intraperitoneal (C) and subcutaneous
(D) lesions. In the endometrial layer of the lesions (e), most blood vessels are DC31 only positive (red arrow-heads in the enlargements);
‘m’=myometrium (aSMA positive cells).
doi:10.1371/journal.pone.0033241.g005
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diagnostic properties with regard to detecting endometriosis
should now be tested in human settings to optimise an efficient
protocol.
Conclusions and possible benefits for the clinical
management of endometriosis
The inability to diagnose non-invasively endometriosis is a
well-recognised clinical issue, because as a consequence, the
correct diagnosis is delayed. Such situation has important
implications on the costs for the health-care system, on the
quality of the private and professional life of the patients and can
compromise the fertility and the functionality of peritoneal organs
[2–4,11,12,16].
A non-invasive diagnostic test for endometriosis would
therefore alleviate all these conditions by allowing an early non-
invasive diagnosis (especially important in young/adolescent
women) and would avoid the costs and the risks of laparoscopy.
Additionally, it would be of great utility for physicians by helping
the selection of patients needing further invasive evaluation/
treatment; helping plan adequately the operation, essential for
treatment success; and helping distinguish recurrent disease from
post-operative fibrosis, which presents similar symptoms as
endometriosis.
Materials and Methods
Mice and surgery
Female Swiss mice were purchased from Harlan (Venray, The
Netherlands) and housed with free access to water and food at the
Central Animal Facilities of Maastricht University. Endometriosis
was surgically induced in nine mice by autologous transplantation
as described before [29]. In short, at 6–8 weeks of age, mice were
anaesthetised using isoflurane (Forane, Abbott laboratories Ltd.,
UK; 5% and 2% in O2 for anaesthesia induction and
maintenance, respectively), the abdomen was shaved and
disinfected with iodine before covering with sterile drapes. A
midline laparotomy was performed and the left uterine horn
ligated proximally and distally with polyglactin 560 sutures,
approximately 1.0 cm apart. Thereafter, the horn segment in
between was resected, opened along its long axis and subsequently
divided in equal halves by cutting perpendicularly to the long axis.
Two uterine fragments of approximately 2–3 mm
2 were prepared
and were fixated using two polypropylene 660 sutures on opposite
sites of the abdominal midline in the same mouse. One specimen
was fixated to the peritoneal side of the abdominal wall with the
endoluminal side facing intraperitoneally. The other specimen was
fixated to the abdominal wall in a subcutaneous pocket with the
endoluminal side towards the abdominal wall. Finally, the
Figure 6. Quantification of new and mature blood vessels. A. The number of CD31 and aSMA positive blood vessels, or vessel density
(number vessels per 100 mm
2) was quantified in: intraperitoneally and subcutaneously induced endometriosis; eutopic endometrium (inside the
uterus); muscular tissue of the abdominal wall either adjacent (peri-endometriotic) or distant to the induced lesions (muscle). The average number of
vessels in each tissue for six mice is shown; statistic is based on unpaired Wilcoxon test: *=0.002; **=0.029; ns=non-significantly different. B. The
ratio between CD31 and aSMA positive blood vessels was calculated in corresponding locations (endometriosis, uterus, peri-endometriosis and
muscle) in each mouse. Afterwards, the average CD31/aSMA ratio in each tissue was computed among the six mice. Statistic based on unpaired
Wilcoxon test: *=0.010; **=0.004; #=0.030; ##=0.019.
doi:10.1371/journal.pone.0033241.g006
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peritoneum, fascia and musculature, and a running intracutaneous
poliglecaprone 560 suture for the skin.
Histology and immunohistochemistry
At sacrifice, induced endometriotic lesions with surrounding
tissues and uterus were excised and the size of the lesions was
assessed with a calliper. Subsequently, tissues were fixed in
buffered formalin, embedded in paraffin and cut in 5 mm thick
sections. For histology, tissues were stained with haematoxylin and
eosin. Immunohistochemistry for cluster of differentiation 31
(CD31; Entrez Gene: PECAM-1, platelet/endothelial cell adhe-
sion molecule) was performed using the rat anti-mouse antibody
clone MEC13.3 (1:100; BD Pharmingen, Breda, The Netherlands)
and proteinase K as antigen retrieval method. Sections were
blocked with 2% rabbit serum, 2% BSA prior to antibody
application. Biotinylated rabbit anti-rat secondary antibody
(1:500; Jackson Immuno Research Laboratories, Inc., PA, USA)
and avidin-biotin-HRP complex (Dako, Carpinteria, CA, USA)
were subsequently used. For detection of pericytes, a-smooth-
muscle-actin (aSMA; Entrez Gene: ACTA2 actin, alpha 2, smooth
muscle, aorta) was employed as a marker. Heat-induced antigen
retrieval in citrate buffer was used, followed by incubation with
monoclonal anti-aSMA FITC-labelled antibody (1:3000; Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands) and by anti-
FITC-HRP conjugated secondary antibody (1:600, Roche Diag-
nostics Co). Diaminobenzidine solution (Dako, Glostrup, Den-
mark) was used as a chromogen.
Vessel density quantification
Microscopy pictures (20X magnification) were taken in the
different tissues in each of the six mice used for quantifications. For
each single tissue 6–12 images were taken for CD31 and equal
number of images for aSMA. Vessel quantification was further
determined on the digital images with aid of the ImageJ program
(National Institute of health, USA; http://rsb.info.nih.gov/ij/).
Vessel number/pixel (1 pixel=0.1 mm) was determined in each
image by counting the CD31 positive and aSMA positive vessels.
Afterwards the average among values obtained from the 6–12
images in each tissue in one mouse was computed to yield the
vessel densities in the various tissues in each mouse.
These final vessel density values were further analysed in
Figure 6. As described in the result section, in Figure 6A the CD31
positive vessel density in each tissue was averaged among the six
mice used for quantification. The same was done for the aSMA
positive vessel density. In Figure 6B, first the ratio CD31/aSMA
positive blood vessels was computed for the various tissues in each
mouse (endometriosis, uterus, peri-endometriosis, muscle). Subse-
quently, the ratios for each tissue were averaged among the six
mice.
Gadofosveset-trisodium
Gadofosveset-trisodium (C33H40GdN3Na3O15P; trisodium-{(2-
(R)-[(4,4-diphenylcyclohexyl)hosphonooxymethyl]diethylenetria-
minepentaacetato) (aquo) gadolinium(III), molecular weight of
975.88 g/mol) was purchased from Bayer AG (Leverkusen,
Germany) under the commercial name Vasovist
TM,a tas t o c k
concentration of 0.25 mMol/ml. For mouse-injection, gadofos-
veset-trisodium was diluted to 18 mM in saline.
MRI
Mice were put under general anaesthesia with 5% isoflurane
(Forane, Abbott laboratories Ltd., UK) in O2. Anaesthesia was
maintained with 2% isoflurane in O2 during the whole MRI
procedure using a breathing mask. Hearth and breath rhythm
were monitored during the whole procedure.
For injecting the contrast agent, an insulin-needle was inserted
into the tail-vein and connected through a 0.61 mm diameter
(0,28 mm internal diameter) PortexH polythene tube (Smiths
Medical International, Ltd, Kent, UK) to a syringe. The tube,
25 cm long, was necessary to operate the contrast agent injection
while the mouse was positioned inside the scanner. Gadofosveset-
trisodium (50 mL of a 18 mM solution) was injected to a final
concentration of 0.03 mMol/Kg (mouse average body weight -
mean6SD - 2962 g), followed by saline injection to flush the
contrast agent through the tube and vein.
Imaging was performed on a 7-Tesla dedicated animal MRI
unit (Bruker Biospec 70/30 USR, BGA12S gradient system,
Paravision 5.03, Bruker Biospin GmbH Ettlingen, Germany).
Images were acquired with a quadrature volume resonator with a
72-mm inner diameter. First, for anatomical reference a set of T2
and T1 weighted images were obtained prior to contrast agent
administration. The acquisition images for the T2-weighted scan
were: 3D TurboRARE spin echo sequence, echo time (TE) 48 ms,
repetition time (TR) 1500 ms, and acceleration (RARE-) factor 16.
The T1 weighted image was also based on a 3D RARE spin echo
pulse sequence: TE 5.4 ms, TR 500 ms, and RARE-factor 4. Both
images were acquired at the same position with identical
geometry. The acquisition matrix 1506150630 and the voxel
sizes were 0.260.260.5 mm for both scans.
Second, angiogenesis sensitive imaging was performed by DCE-
MRI, which was based on multi-slice fast gradient echo sequence
[21–23]. The sequence properties were TE 1.75 ms, TR 83 ms,
flip angle 35u, 75 volume repetitions, matrix size of 1506150, pixel
size 0.2602 mm, 15 slices, 1-mm contiguous slice thickness. After
a period of 90 seconds (approximately 4 repetitions) the contrast
agent was injected within five seconds. In this procedure, the low-
resolution MR images were serially acquired for 20 minutes after
contrast agent injection. After DCE-MRI the above described
anatomical T1 and T2 weighted scans were repeated with the
same receiver amplifier gain settings to facilitate image subtrac-
tion.
Image analysis
To quantify the dynamics of the contrast agent enhancement,
the area-under-curve values were determined at different charac-
teristic stages of the signal intensity curves (Figure 4B) in various
regions of interest: (i) the area (denoted by ‘I’ from inwash) from
the contrast agent arrival till the peak enhancement; (ii) the area
(denoted by ‘C’ from circulation phase) from peak enhancement
till 10 minutes after contrast injection; and (iii) the area (denoted
by ‘O’ from outwash) from 10 minutes till 20 minutes after
contrast agent injection. Characterisation of tissue enhancement
was quantified by the ratio O/C.
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